6533b835fe1ef96bd129ec5e
RESEARCH PRODUCT
GABAA-receptor Subtypes: Clinical Efficacy and Selectivity of Benzodiazepine Site Ligands
Mauri J. MattilaEsa R. KorpiHartmut LüddensWilliam Wisdensubject
ZolpidemPyridinesmedicine.drug_classNonbenzodiazepinePharmacologyLigandsAnxiolyticHypnoticBenzodiazepines03 medical and health sciences0302 clinical medicineReceptors GABAmedicineHumansHypnotics and Sedatives030304 developmental biologyNeurotransmitter Agents0303 health sciencesBenzodiazepineBinding SitesGABAA receptorbusiness.industryGeneral Medicine3. Good healthZolpidemMechanism of actionSedativemedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugdescription
The main inhibitory neurotransmitter receptor of the brain, the gamma-aminobutyric acid type A receptor (GABA[A]), mediates the actions of several classes of clinically important drugs, such as benzodiazepines, barbiturates and general anaesthetics. This review summarizes the current knowledge on how classical benzodiazepines and novel nonbenzodiazepine compounds act on the benzodiazepine site of GABA(A) receptors and on their clinical pharmacology related to anxiolytic, sedative, hypnotic and cognitive effects or side-effects. Partial agonism, receptor subtype selectivity and novel binding sites are discussed as possible strategies to develop new drugs with fewer adverse effects than are seen in the clinical use of benzodiazepines.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1997-08-01 | Annals of Medicine |